CureVac’s mRNA based Vaccine Candidate against SARS-CoV-2

Data update: [redacted]
Pre-read for: EU Member state experts review
- STRICTLY CONFIDENTIAL -
Key elements (1/2)

1. CureVac's mRNA platform
   - Pioneer in developing mRNA vaccines and therapies; broad IP position:
   - CureVac's
   - External validation of platform: Strategic partnerships with

2. CVnCoV construct and preclinical data
   - Clinical COVID-19 vaccine candidate selected based on biological properties (preclinical immunogenicity and safety) characterized in vitro and in vivo (mice and rats) and large scale manufacturability

3. Available CVnCoV Ph1 clinical data
   - 
   - 
   - 

CureVac - CvnCoV - strictly confidential -
Key elements (2/2)

4. Clinical development plan and project timelines

5. Manufacturing footprint, capacity and delivery plan

6. Target presentation and shelf-life
1. CureVac’s mRNA Platform
Creates Unique, IP-protected Product Candidates

1. Identification of a target expression profile for each mRNA product candidate

2. Provides optimal mRNA solutions for each target indication

3. The optimization process allows us to pursue new and exclusive IP protection for each product candidate across our focus areas and proprietary technologies

Target profile

RNAoptimizer®

Protein Design

mRNA Delivery

mRNA Optimization

Areas of focus

- Oncology
- Prophylactic Vaccines
- Protein Therapy

Strictly Private & Confidential
Protein Design: Enables the Optimization of Specific Properties of the Encoded Protein
2. CVnCoV Construct and Pre-Clinical Data
Fast-Track SARS-CoV-2 Vaccine Development

Development Plan overview and timeline
CVnCoV Induces
CVnCoV Induces a
Characterization of humoral and cellular responses:
Values in $\log(x)$
3. Available CVnCoV Clinical Data
Overview of Clinical Study Design of
Ongoing Phase 1 Results Indicate

Systemic and Local Solicited Events by Dose Level and Dosing Occasion
(as % of subjects at each time point)
4. Clinical Development Plan and Project Timelines
• Study

• Study goal:

Initial Phase

- Participants will be enrolled

Expansion Phase

• • •
CureVac will
# Key Project Milestones

<table>
<thead>
<tr>
<th>#</th>
<th>Milestone</th>
<th>Planned Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
5. Manufacturing Footprint, Capacity Increase and Delivery Plan for EU APA
6. Vaccine Presentation and Shelf-Life
CVnCoV Presentations Upon Approval
Target stability

Ongoing data collection to support target stability profile

Perspective on feasibility of achieving target profile
Stability Data for